1.57k followers • 10 symbols Watchlist by Yahoo Finance
This basket consists of stocks that benefit from the needs of aging baby boomers.
UnitedHealth Group (UNH) closed at $249.64 in the latest trading session, marking a -1.05% move from the prior day.
The U.S. Food and Drug Administration has approved Allergan Plc's CoolTone device for use in strengthening, toning and firming the abdominal area, buttocks and thighs, Allergan said Monday. CoolTone uses magnetic muscle stimulation to penetrate muscle layers, which then causes involuntary muscle contractions. The body responds to the contractions by strengthening muscle fibers, leading to increased muscle tone. The drugmaker said CoolTone has 50% more magnetic intensity than the leading competitor, but that claim has not been clinically established. Allergan also makes the CoolSculpting device, a non-surgical fat-elimination device that works by freezing and killing fat cells in targeted areas like the abdomen, flanks or under the chin. Shares of the drugmaker have fallen 3.4% so far this year, but were down as much as 12.5% in June before buzz of a possible company split helped bolster the stock price. Allergan has been dealing with some significant issues in the past year -- investors are worried about the future of Botox, the company's biggest earner, as it faces competition in the anti-wrinkle and injectable migraine treatment markets. Investors were also rattled by the failure of depression drug rapastinel -- once considered by many to be Allergan's next big blockbuster drug -- in clinical trials earlier this year. In May, Chief Executive Brent Saunders said he had heard investors' concerns "loud and clear," adding that "everything is on the table," including the possibility of splitting the company up.
Royal Caribbean Cruises Ltd. has formed a new company through a joint venture that will develop, own and operate destinations in coastal cities. The new company, called Holistica Destinations Ltd., is a 50-50 partnership between the Miami-based cruise company (NYSE: RCL) and Mexico-based ITM Group. The two companies are searching for a CEO for Holistica, which will be headquartered in Miami.
Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.
President Donald Trump will sign an executive order aimed at requiring hospitals to be more transparent about prices before charging patients for healthcare services, Secretary of Health and Human Services Alex Azar said on Monday. The executive order will direct HHS to issue a rule that will mandate hospitals to disclose in an "easy-to-read, patient-friendly format" what prices patients and insurers will actually end up paying, Azar said. The order will ultimately require healthcare providers and insurers to provide patients with information about the out-of-pocket costs they'll face before they receive healthcare services, he said.
Church & Dwight’s (CHD) earnings have grown at a strong double-digit rate in the past several quarters and have outpaced those of its rivals. The company has surpassed Wall Street’s expectations in five out of the past six quarters.
Under Estée Lauder chief Fabrizio Freda, one of our 2019 World’s Best CEOs, the company has conquered new markets and pumped up growth. Why Chinese millennials outspend their American counterparts.
The Dow Jones Industrial Average ended down Friday, but held onto most of the week's gains following reports that President Donald Trump ordered, but then rescinded, an airstrike on military installations in Iran. Canopy Growth is Real Money's Stock of the Day. advanced following a report in The Wall Street Journal that the company was ready to buy healthcare payments group Equian LLC for around $3.2 billion.
Does the June share price for Service Corporation International (NYSE:SCI) reflect what it's really worth? Today, we...
Interestingly, June 21 marks the official start of summer, and the summer months often bring lethargy in the equity markets, particularly on Fridays. That was the case today as stocks, broadly speaking, were mostly listless.Source: Shutterstock To close the week, the S&P 500 fell a scant 0.13%, and the Nasdaq Composite lost 0.24%. The Dow Jones Industrial Average also lost 0.13%. Long-term investors can find some solace on the day of the summer solstice with an article in Barron's today indicating Dow 30,000 could arrive sooner than expected."To stick with our 2025 forecast now would be to suggest that stocks over the next 5½ years will climb just 2.1% a year, plus dividends," according to Barron's. "It's possible, but pessimistic. The Dow could reach 30,000 much sooner than 2025."InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe article indicates it is possible the Dow sees 30,000 sometime in 2021, a bullish forecast considering the blue-chip index closed around 26,800 today.That is a long-term forecast. Over the near-term, the Federal Reserve will likely dominate the conversation and that is not surprising. For investors hoping for rate cut this year, good news: Fed funds traders bet on such a move in record fashion this week, according to CNBC. Some Mild WinnersBy the end of the day, just two of the 30 Dow Jones stocks were sporting gains of 1% or more. The clear powerhouse was UnitedHealth Group (NYSE:UNH), which gained 1.82% on new that it is acquiring health-care payments provider Equian LLC for $3.2 billion. * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 That is a drop in the bucket for UnitedHealth, which has a market capitalization of $240 billion and a stellar return for Equian's private equity owner New Mountain, which purchased the company four years ago for just $225 million.Defensive names have been getting some attention here in recent weeks and with good reason. Today, Dow component Walmart (NYSE:WMT), on essentially no news to merit a move like this, jump 0.73% to hit an all-time high. The largest U.S. retailer is up almost 20% year-to-date.Pharmaceuticals giant Pfizer (NYSE:PFE) added 0.88% after the European Commission approved the company's TALZENNA treatment for breast cancer patients. The U.S. Food and Drug Administration (FDA) approved the treatment last October."We are thrilled that we can now offer these patients in Europe, who are often diagnosed at a younger age and have limited treatment options, an effective, once-daily, alternative treatment to chemotherapy," said Pfizer in a statement.Staying in the blue-chip pharmaceuticals space, Merck & Co. (NYSE:MRK) closed modestly lower, but three analysts raised price targets on the stock to $90, $95 and $96, respectively. In either case, that is some decent upside from Merck's Friday close around $84.50. Bottom Line on the Dow Jones TodayWith all the talk about a potential rate cut, investors should not forget that second-quarter earnings season will soon be here. While glum earnings may be baked into the market at current levels, investors should still expect some less-than-positive sentiment around the second-quarter numbers."As of today, the estimated earnings decline for the second quarter for the S&P 500 stands at -2.6%," said FactSet in a note out Friday. "If -2.6% is the actual earnings decline for the quarter, it will mark the first time the index has reported two straight quarters of year-over-year declines in earnings since Q1 2016 and Q2 2016. It will also mark the largest year-over-year decline in earnings since Q2 2016 (-3.2%)."Unfortunately, the same note indicates analysts are ratcheting down third-quarter estimates with the energy and technology sectors looking like the worst offenders.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 * 5 Boring Stocks to Buy This Summer * 7 S&P 500 Stocks to Buy With Little Debt and Lots of Profits Compare Brokers The post Dow Jones Today: A Typical Summer Friday appeared first on InvestorPlace.
The Dow Jones came to within 44 points of its all-time high Friday but backed off highs. UnitedHealth and Exxon Mobil were top gainers in the Dow.
Are traditional retail pharmacies and insurance companies worried about Amazon.com, Inc. (NASDAQ: AMZN )'s push into their respective territories? Public comments from management teams brush off any concerns, ...
shares edged lower Friday following report that it's ready to buy healthcare payments group Equian LLC for around $3.2 billion. The Wall Street Journal said the deal would see Equian sold by its private equity owners, Mountain Capital, and likely merged into UnitedHealth's Optum division, which recently closed its $4.3 billion purchase of DaVita medical group after getting Federal Trade Commission approval on Wednesday. UnitedHealth must now sell one of DaVita's units in Las Vegas to a Utah-based group called Intermountain Healthcare in order to abide by the FTC's decision.
Carnival's (CCL) top-line improvement in second-quarter fiscal 2019 can be attributed strength in passenger tickets, and onboard and other as well as tour and other businesses.
Allergan PLC said Friday that its supplemental biologics application (sBLA) for Botox for the treatment of upper limb spasticity in pediatric patients, from ages 2 to 17, was approved by the U.S. Food and Drug Administration. Botox was granted a 6-month Priority Review by the FDA. Upper limb spasticity often results in muscle tightness and stiffness, and can interfere with movement at the joints. Common causes of spasticity in children include cerebral palsy, traumatic brain injury, multiple sclerosis, spinal cord injury and stroke. Allergan said the FDA is also reviewing an sBLA for the use of Botox to treatment pediatric patients with lower limb spasticity, and expects a decision by the end of the year. Allergan's stock, which is still inactive in premarket trade, has fallen 15% over the past three months, while the SPDR Health Care Select Sector ETF has gained 1.1% and the S&P 500 has tacked on 3.5%.
UnitedHealth Group Inc., which just closed on a multibillion-dollar acquisition this week, isn't waiting long for its next big deal: The Wall Street Journal reports that the insurance giant has agreed to buy Equian, which processes health care payments.